Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    Darovasertib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    IDEAYA Reveals Phase 2 Data for Darovasertib in Uveal Melanoma
    IDEAYA Reveals Phase 2 Data for Darovasertib in Uveal Melanoma

    08 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-positive-interim-phase-2-data-for-darovasertib-in-the-neoadjuvant-setting-of-primary-uveal-melanoma-302548579.html

    PR NEWSWIRE
    08 Sep 2025
    Share Share
    Servier Commits up To $530 M Into Eye Cancer Deal with Ideaya
    Servier Commits up To $530 M Into Eye Cancer Deal with Ideaya

    03 Sep 2025

    // PRESS RELEASE

    https://ir.ideayabio.com/2025-09-02-Servier-and-IDEAYA-Biosciences-Partner-to-Bring-Darovasertib,-a-Promising-Uveal-Melanoma-Treatment,-to-Patients-Worldwide

    PRESS RELEASE
    03 Sep 2025
    Share Share
    Ideaya Biosciences to Unveil Phase 2 Darovasertib/Crizotinib
    Ideaya Biosciences to Unveil Phase 2 Darovasertib/Crizotinib

    30 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-to-present-first-median-overall-survival-data-from-phase-2-trial-of-the-darovasertib--crizotinib-combination-in-metastatic-uveal-melanoma-at-the-2025-society-for-melanoma-research-congress-302542236.html

    PR NEWSWIRE
    30 Aug 2025
    Share Share
    IDEAYA Announces Phase 2 Darovasertib Trial Presents at ESMO 2025
    IDEAYA Announces Phase 2 Darovasertib Trial Presents at ESMO 2025

    24 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-proffered-paper-oral-presentation-at-esmo-2025-for-phase-2-clinical-trial-of-neoadjuvant-darovasertib-in-primary-uveal-melanoma-302513177.html

    PR NEWSWIRE
    24 Jul 2025
    Share Share
    IDEAYA Biosciences Announces FDA Type D Meeting for Darovasertib
    IDEAYA Biosciences Announces FDA Type D Meeting for Darovasertib

    14 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-successful-fda-type-d-meeting-on-phase-3-registrational-trial-design-for-darovasertib-as-neoadjuvant-therapy-for-primary-uveal-melanoma-302427143.html

    PR NEWSWIRE
    14 Apr 2025
    Share Share
    IDEAYA Bio gets FDA Breakthrough for Darovasertib in Uvea Melanoma
    IDEAYA Bio gets FDA Breakthrough for Darovasertib in Uvea Melanoma

    31 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-receives-us-fda-breakthrough-therapy-designation-for-darovasertib-monotherapy-in-neoadjuvant-uveal-melanoma-302415020.html

    PR NEWSWIRE
    31 Mar 2025
    Share Share